Why is Glenmark Pharma falling/rising?

As of 17-Jul, Glenmark Pharmaceuticals Ltd. is experiencing a price increase, currently at Rs 2,226.65, reflecting a rise of 23.75 points or 1.08%. The stock has shown strong performance, with a 1-week return of +16.88% and a 1-month return of +34.64%, significantly outperforming the Sensex, which has seen a decline of -1.12% over the same week and a modest increase of +0.83% over the month. Today's trading activity indicates that the stock is close to its 52-week high, just 2.87% away, and has outperformed its sector by 0.47%. Despite a decrease in investor participation, as evidenced by a 63.58% drop in delivery volume compared to the 5-day average, the stock remains liquid enough for trading. The company's strong fundamentals, including a low Debt to EBITDA ratio of 1.00 times and positive quarterly results, have contributed to its upward momentum.
In the broader market context, Glenmark Pharmaceuticals has significantly outperformed the benchmark indices over various time frames, including a remarkable 485.27% return over the past three years compared to the Sensex's 53.01%. This strong performance is bolstered by high institutional holdings at 37.8%, indicating confidence from more knowledgeable investors. The consistent returns over the last year, with a 58.02% increase, further highlight the stock's resilience and attractiveness in a challenging market environment. Overall, the combination of strong financial performance, positive investor sentiment, and favorable comparisons to the benchmark supports the stock's rising price.